A PHP Error was encountered

Severity: Notice

Message: Only variable references should be returned by reference

Filename: core/Common.php

Line Number: 257

A PHP Error was encountered

Severity: Warning

Message: Cannot modify header information - headers already sent by (output started at /home/biomagaz/cwcms_core/system/core/Exceptions.php:185)

Filename: core/Security.php

Line Number: 188

A PHP Error was encountered

Severity: Warning

Message: Cannot modify header information - headers already sent by (output started at /home/biomagaz/cwcms_core/system/core/Exceptions.php:185)

Filename: libraries/Session.php

Line Number: 672

BIO Magazine - Biotech Industry Expected to Experience More M&A Activity in 2013 Δεκέμβριος 2015
Δεκέμβριος 2015 No38

BIO Finance

Biotech Industry Expected to Experience More M&A Activity in 2013
Biotech Industry Expected to Experience More M&A Activity in 2013

NEW YORK, NY--(Marketwire - Jan 21, 2013) - Lost revenues from expiring patents has played a major part in the Biotech Industry's success in recent years.A total of 676 takeovers of biotechnology and pharmaceutical companies have occurred in the past three years, with an average premium of 38 percent, according to data collected by Bloomberg. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on BG Medicine, Inc. (NASDAQBGMD) and YM BioSciences Inc. (NYSEYMI) (TSXYM).

At the end of the third quarter five of the biggest drug makers in the U.S. held over $70 billion in cash, near cash and short-term investments. Major revenue losses from patent expirations have forced big pharmaceutical companies to look to biotech companies to help fill the void. Pfizer's Lipitor and Bristol-Myers' Plavix, which lost exclusivity in late 2011, had combined annuals revenues of $17 billion at their peaks.

"We're through many cost-cutting programs, restructurings and portfolio arrangements," said Henry Gosebruch, Managing Director, Mergers & Acquisitions J.P. Morgan. "When you put that together with record levels of cash available and improving, but still moderate R&D productivity, we think there will be more big pharma M&A activity in 2013."

Five Star Equities releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free atwww.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

BG Medicine is a diagnostics company focused on the development and commercialization of novel cardiovascular tests to address significant unmet medical needs, improve patient outcomes and reduce healthcare costs. The company' BGM Galectin-3 blood test has recently obtained a CE Mark.

YM BioSciences Inc. is a drug development company primarily focused on advancing CYT387, an orally administered inhibitor of both the JAK1 and JAK2 kinases, which have been implicated in a number of hematological and immune cell disorders including myeloproliferative neoplasms and inflammatory diseases as well as certain cancers.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:

www.FiveStarEquities.com/disclaimer

http://finance.yahoo.com/news/biotech-industry-expected-experience-more-132000756.html

<< Επιστροφή στην λίστα

© BIO | info@biomagazine.gr

Powered by CreativeWorks